363 related articles for article (PubMed ID: 33131340)
1. Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review.
Ritondo BL; Puxeddu E; Calzetta L; Cazzola M; Rogliani P
Expert Opin Pharmacother; 2021 Apr; 22(5):611-620. PubMed ID: 33131340
[No Abstract] [Full Text] [Related]
2. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
Bourdin A; Molinari N; Ferguson GT; Singh B; Siddiqui MK; Holmgren U; Ouwens M; Jenkins M; De Nigris E
Adv Ther; 2021 Jun; 38(6):3089-3112. PubMed ID: 33929661
[TBL] [Abstract][Full Text] [Related]
5. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
6. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
Heo YA
Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
[TBL] [Abstract][Full Text] [Related]
7. LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data.
Gong Y; Sui Z; Lv Y; Zheng Q; Li L
Eur J Clin Pharmacol; 2023 Oct; 79(10):1321-1332. PubMed ID: 37507595
[TBL] [Abstract][Full Text] [Related]
8. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
Rhee CK; Yoshisue H; Lad R
Adv Ther; 2019 Mar; 36(3):495-519. PubMed ID: 30742242
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
Beeh KM; Rothnie KJ; Claussen J; Hardtstock F; Knapp RK; Wilke T; Czira A; Compton C; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2024; 19():945-956. PubMed ID: 38646606
[TBL] [Abstract][Full Text] [Related]
10. Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score.
Rogliani P; Ora J; Cavalli F; Cazzola M; Calzetta L
J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956108
[TBL] [Abstract][Full Text] [Related]
11. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
12. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
Calzetta L; Di Marco F; Blasi F; Cazzola M; Centanni S; Micheletto C; Rossi A; Rogliani P
Pulm Pharmacol Ther; 2019 Dec; 59():101855. PubMed ID: 31639476
[TBL] [Abstract][Full Text] [Related]
13. Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease.
Singh D
Expert Opin Pharmacother; 2018 Aug; 19(11):1279-1287. PubMed ID: 29985096
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
Plate T; Friedrich FW; Beier J
Int J Chron Obstruct Pulmon Dis; 2020; 15():1335-1347. PubMed ID: 32606643
[TBL] [Abstract][Full Text] [Related]
15. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
Solidoro P; Patrucco F; Bagnasco D
Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
[No Abstract] [Full Text] [Related]
16. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
17. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease.
Kupczyk M; Kuna P
Expert Rev Respir Med; 2019 Jan; 13(1):5-11. PubMed ID: 30463457
[TBL] [Abstract][Full Text] [Related]
18. Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations.
Usmani OS; Scichilone N; Mignot B; Belmans D; Van Holsbeke C; De Backer J; De Maria R; Cuoghi E; Topole E; Georges G
Int J Chron Obstruct Pulmon Dis; 2020; 15():2433-2440. PubMed ID: 33116458
[TBL] [Abstract][Full Text] [Related]
19. Triple inhaled therapy for chronic obstructive pulmonary disease.
Montuschi P; Malerba M; Macis G; Mores N; Santini G
Drug Discov Today; 2016 Nov; 21(11):1820-1827. PubMed ID: 27452453
[TBL] [Abstract][Full Text] [Related]
20. Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
Feldman WB; Avorn J; Kesselheim AS; Gagne JJ
JAMA Intern Med; 2023 Jul; 183(7):685-695. PubMed ID: 37213116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]